Tag Archives: bmy

Incyte Hits High On Cancer Drug Data, Buyout Talk

Incyte (INCY) stock hit a 15-year high Friday after the release of new clinical-trial data on the biotech’s cancer drug epacadostat, following a fresh round of buyout speculation this week. A release of abstracts for presentations at the European Society for Medical Oncology (ESMO) assembly next weekend included Incyte’s trial of epacadostat in combination with Bristol-Myers Squibb’s (BMY) Yervoy to treat melanoma. Though it was a small study with

Lilly, Bristol-Myers Beat Q2 Views, Lift Guidance

Big pharmas Eli Lilly (LLY) and Bristol-Myers Squibb (BMY) both soundly beat Q2 earnings estimates Thursday morning. Both also raised guidance, but not as much as their quarterly beats seemed to warrant. Lilly’s profit, excluding one-time items, rose 22% over the year-earlier quarter to 90 cents a share, beating analysts’ consensus by 16 cents, according to Thomson Reuters. Revenue rose 1% to $4.98 billion, where analysts had expected a slight

Valeant Earnings Soar On M&A, Organic Sales Growth

Acquisition-hungry Valeant Pharmaceuticals (VRX) rose more than 5% in the stock market today to a record high, despite weak Q3 earnings guidance, after neatly stepping over analysts’ second-quarter revenue and earnings expectations. Valeant was one of several drugmakers and biotechs to report Thursday morning, including Celgene (CELG), Eli Lilly (LLY), Shire (SHPG) and Bristol-Myers Squibb (BMY) . The Laval, Quebec-based drugmaker said total